Who to call at aTyr Pharma, Inc., and when
Fundz watches for the moments aTyr Pharma, Inc. starts buying, and tells you who to reach.
- An alert the day aTyr Pharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at aTyr Pharma, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at aTyr Pharma, Inc.. With Fundz connected, it knows.
aTyr Pharma, Inc.
The company reported another event it considers important. An 8-K is the notice a US public company must file within four business days of a major event.
atyrpharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
aTyr Pharma filed a prospectus supplement on November 6, 2026, to offer up to $79.99 million in common stock under an existing Open Market Sale Agreement with Jefferies LLC. The capital raise supports ongoing operations and product development initiatives.
Quick answer
aTyr Pharma, Inc. filed a Form 8-K with the SEC on November 6, 2026 under Item 8.01 (Other Events). aTyr Pharma filed a prospectus supplement on November 6, 2026, to offer up to $79.99 million in common stock under an existing Open Market Sale Agreement with Jefferies LLC.
- What did aTyr Pharma, Inc. disclose in its 8-K filed November 6, 2026?
- aTyr Pharma filed a prospectus supplement on November 6, 2026, to offer up to $79.99 million in common stock under an existing Open Market Sale Agreement with Jefferies LLC. The capital raise supports ongoing operations and product development initiatives.
- What does 8-K Item 8.01 (Other Events) mean?
- The company reported another event it considers important.
- Which other companies filed an 8-K Item 8.01 around the same time?
- Morgan Stanley Investment Management Inc. (November 4, 2026), UFP Industries, Inc. (November 4, 2026) and Mid Penn Bancorp, Inc. (November 2, 2026) also filed an Item 8.01 8-K within a week of aTyr Pharma, Inc.
- Where can I read the original aTyr Pharma, Inc. filing?
- The original filing is on SEC EDGAR (CIK 0001339970), accession number 0001339970-26-000085.
Source: Fundz verified event record.
Other companies that filed an 8-K Item 8.01 (Other Events) the same week
Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.
- Morgan Stanley Investment Management Inc. (November 4, 2026): Morgan Stanley Investment Management appointed Swapnil Parab as Chief Financial Officer effective November 4, 2026, succeeding Sally Diffley who resigned on October 30, 2026.
- UFP Industries, Inc. (November 4, 2026): UFP Industries appointed Scott Worthington as Vice President of Investor Relations, transitioning him from his role as president of UFP Packaging, effective November 2026.
- Mid Penn Bancorp, Inc. (November 2, 2026): Mid Penn Bancorp announced the hiring of Rob Curley, III as President of the Eastern Division of Mid Penn Bank, effective late-November 2026.
Key Takeaways
aTyr Pharma is pursuing an equity offering of approximately $80 million through a prospectus supplement filed with the SEC
The offering is conducted under an Open Market Sale Agreement with Jefferies LLC, originally established in April 2022 and amended in December 2024
2 more takeaways
Related Filings (1)
1 more filing from aTyr Pharma, Inc. in the last 90 days
Filing Overview
What This Means
aTyr Pharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.